Keytruda

Akeso
Favicon Fierce Pharma

Akeso, Summit's ivonescimab ups PD-1 in chemo combo in 1L NSCLC

HARMONi-6 marks the first phase 3 trial in which a regimen has beaten the combination of a PD-1 inhibitor and chemotherapy on PFS in first-line NSCLC.
Angus Liu Oct 19, 2025 10:45am
green light go go ahead advance yes streetlight

Moderna posts melanoma data behind decision to say 'I do' to IDO

Oct 13, 2025 5:15am
next step ladder climb succeed win

PDS reports 39 months OS in phase 2 head and neck cancer trial

Aug 25, 2025 9:00am
Tecentriq
Favicon Fierce Pharma

Roche touts Tecentriq biomarker win in bladder cancer

Aug 18, 2025 4:17pm
dart board miss failure

Cancer vaccine's 'narrow' fail won't stop IO heading to FDA

Aug 11, 2025 9:48am
Merck Co
Favicon Fierce Pharma

Merck unveils $3B cost-cutting plan

Jul 29, 2025 8:15am